Medical Xpress July 31, 2025
Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic leukemia (CMML), a rare and aggressive form of blood cancer.
CMML is notoriously difficult to treat, with limited options and a low survival rate. Current therapies often lead to only short-term responses in a small number of patients.
The PREACH-M trial is investigating a combination of the standard therapy azacitidine with an investigational antibody called Lenzilumab. Invented in Australia, the drug works by blocking a key signaling molecule that drives the overproduction of abnormal blood cells and inflammation in people with CMML and related leukemias. By neutralizing this molecule, lenzilumab aims to restore balance in the blood and reduce disease-related symptoms.
Interim results...
Today's Sponsors
Today's Sponsor